



CathRx Ltd  
ABN 23 089 310 421  
5 Parkview Drive  
Homebush Bay NSW 2127  
Australia  
Telephone +61 (0)2 9397 5700  
Facsimile +61 (0)2 9397 5701  
www.cathrx.com

## **ASX Announcement**

### **CathRx receives CE Mark approval for its first therapeutic catheter designed to treat cardiac arrhythmias**



#### **SYDNEY Australia 24 March 2011**

Cardiac catheter manufacturer CathRx Limited (ASX:CXD) today announced that it has received CE Marking for its first generation irrigated ablation catheter coupled with the Company's variable deflectable stylet. This catheter is the first approved catheter in the Company's catheter range designed for use in the treatment of cardiac arrhythmias.

CathRx Chief Executive Officer, Jeff Goodman said, "Now that we have this CE Mark approval, we have demonstrated a capability to produce a complete catheter offering for the diagnosis and treatment of atrial flutter and atrial fibrillation.

I am also pleased to report that our second generation therapeutic catheter range development programme is progressing on time and on budget and I believe the approval of the first generation will facilitate the approval of the second generation products in a timely manner.

It is not CathRx's current intention to market the approved first generation therapeutic catheter range until after current partnership negotiations are complete."

**End**

#### **About CathRx**

CathRx is a medical device company which manufactures and markets advanced cardiac catheter solutions for the treatment of people suffering from electrical problems of the heart known as cardiac arrhythmias. CathRx's proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to successfully treat patients with speed, safety and precision. CathRx's diagnostic products are now being sold in Europe.

#### **About cardiac arrhythmias**

Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. Atrial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the



CathRx Ltd  
ABN 23 089 310 421

5 Parkview Drive  
Homebush Bay NSW 2127  
Australia  
Telephone +61 (0)2 9397 5700  
Facsimile +61 (0)2 9397 5701  
[www.cathrx.com](http://www.cathrx.com)

problem and can have side effects. Physicians worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.

***For further information:***

Jeffrey Goodman  
CathRx Chief Executive Officer  
Telephone: +61 2 9397 5700

Amanda Wong  
CathRx Chief Financial Officer  
Telephone: +61 2 9397 5700

